{
  "dataset_metadata": {
    "name": "VITAL Confidence Validation Dataset",
    "version": "1.0.0",
    "created_date": "2025-10-24",
    "description": "Expert-labeled dataset for validating confidence calculation accuracy",
    "total_samples": 120,
    "labeling_criteria": {
      "high_quality": "0.85-0.95: Expert-level response with strong evidence, comprehensive coverage, perfect alignment",
      "medium_quality": "0.65-0.84: Good response with decent evidence, adequate coverage, good alignment",
      "low_quality": "0.30-0.64: Basic response with weak/no evidence, incomplete coverage, poor alignment"
    },
    "target_accuracy": ">=85% agreement between calculated and ground truth confidence (within ±0.10)"
  },

  "samples": [
    {
      "id": "val_001",
      "domain": "regulatory",
      "query": "What are the FDA requirements for 510(k) premarket notification for Class II devices?",
      "response": "FDA 510(k) premarket notification for Class II devices requires: (1) Demonstration of substantial equivalence to a legally marketed predicate device, (2) Detailed device description including intended use, technological characteristics, and performance data, (3) Biocompatibility testing per ISO 10993 if device contacts patient, (4) Sterilization validation if applicable, (5) Software documentation per FDA guidance if device includes software, (6) Clinical data if performance testing alone insufficient, (7) Labeling including instructions for use and contraindications. Submission reviewed within 90 days, though FDA may request additional information extending timeline to 3-12 months.",
      "agent_metadata": {
        "name": "Regulatory Expert",
        "tier": 1,
        "specialties": ["fda_regulatory", "quality_assurance"],
        "domain": "regulatory"
      },
      "rag_results": [
        {
          "similarity": 0.94,
          "metadata": {
            "document_type": "regulatory_guidance",
            "evidence_level": 1,
            "specialty": "fda_regulatory"
          }
        },
        {
          "similarity": 0.91,
          "metadata": {
            "document_type": "regulatory_standard",
            "evidence_level": 1,
            "specialty": "fda_regulatory"
          }
        },
        {
          "similarity": 0.88,
          "metadata": {
            "document_type": "regulatory_guidance",
            "evidence_level": 2,
            "specialty": "quality_assurance"
          }
        }
      ],
      "ground_truth_confidence": 0.92,
      "ground_truth_quality": "high",
      "reasoning": "Perfect regulatory alignment, high-quality FDA guidance sources, comprehensive response covering all key requirements with specific standards cited",
      "expected_breakdown": {
        "rag_confidence": "0.90-0.95",
        "alignment_confidence": "0.88-0.93",
        "completeness_confidence": "0.88-0.93"
      }
    },

    {
      "id": "val_002",
      "domain": "regulatory",
      "query": "What are the FDA requirements for Class II devices?",
      "response": "Class II devices need 510(k) clearance and quality system compliance.",
      "agent_metadata": {
        "name": "Regulatory Expert",
        "tier": 1,
        "specialties": ["fda_regulatory"],
        "domain": "regulatory"
      },
      "rag_results": [
        {
          "similarity": 0.68,
          "metadata": {
            "document_type": "general_guidance",
            "evidence_level": 3
          }
        }
      ],
      "ground_truth_confidence": 0.45,
      "ground_truth_quality": "low",
      "reasoning": "Very incomplete response, lacks detail on 510(k) requirements, no mention of specific standards, poor RAG quality, though agent specialty matches",
      "expected_breakdown": {
        "rag_confidence": "0.30-0.45",
        "alignment_confidence": "0.75-0.85",
        "completeness_confidence": "0.20-0.35"
      }
    },

    {
      "id": "val_003",
      "domain": "clinical",
      "query": "What are the primary endpoints for cardiovascular clinical trials?",
      "response": "Primary endpoints for cardiovascular trials typically include: (1) Major Adverse Cardiovascular Events (MACE) - composite of cardiovascular death, myocardial infarction, and stroke, (2) All-cause mortality for mortality-focused trials, (3) Hospitalization for heart failure in HF trials, (4) Change in surrogate markers like LDL-C for lipid-lowering trials, (5) Exercise tolerance or functional capacity (6-minute walk test, peak VO2), (6) Quality of life measures (KCCQ, EQ-5D). Selection depends on therapeutic area, disease stage, and regulatory guidance (FDA Cardiovascular Guidance 2019).",
      "agent_metadata": {
        "name": "Clinical Researcher",
        "tier": 2,
        "specialties": ["clinical_research", "cardiology"],
        "domain": "clinical"
      },
      "rag_results": [
        {
          "similarity": 0.89,
          "metadata": {
            "document_type": "clinical_guidance",
            "evidence_level": 1,
            "specialty": "cardiology"
          }
        },
        {
          "similarity": 0.86,
          "metadata": {
            "document_type": "research_protocol",
            "evidence_level": 2,
            "specialty": "clinical_research"
          }
        },
        {
          "similarity": 0.82,
          "metadata": {
            "document_type": "clinical_standard",
            "evidence_level": 2
          }
        }
      ],
      "ground_truth_confidence": 0.84,
      "ground_truth_quality": "high",
      "reasoning": "Tier 2 agent with excellent specialty match, high-quality clinical evidence, comprehensive response with specific examples and FDA guidance citation. Slightly lower than Tier 1 due to agent tier.",
      "expected_breakdown": {
        "rag_confidence": "0.85-0.90",
        "alignment_confidence": "0.82-0.87",
        "completeness_confidence": "0.85-0.90"
      }
    },

    {
      "id": "val_004",
      "domain": "clinical",
      "query": "What are cardiovascular endpoints?",
      "response": "Common endpoints include death, heart attack, and stroke.",
      "agent_metadata": {
        "name": "Clinical Researcher",
        "tier": 2,
        "specialties": ["clinical_research"],
        "domain": "clinical"
      },
      "rag_results": [],
      "ground_truth_confidence": 0.38,
      "ground_truth_quality": "low",
      "reasoning": "No RAG results, very basic response lacking detail, no mention of MACE composite, surrogate markers, or quality of life measures. Tier 2 agent without specialty match.",
      "expected_breakdown": {
        "rag_confidence": "0.15-0.30",
        "alignment_confidence": "0.50-0.65",
        "completeness_confidence": "0.25-0.40"
      }
    },

    {
      "id": "val_005",
      "domain": "medical",
      "query": "What are the contraindications for anticoagulation therapy in atrial fibrillation patients?",
      "response": "Absolute contraindications for anticoagulation in AF include: (1) Active bleeding or high bleeding risk (recent hemorrhagic stroke, GI bleed <6 months), (2) Severe thrombocytopenia (platelets <50,000), (3) Intracranial hemorrhage history, (4) Severe liver disease with coagulopathy. Relative contraindications: (1) Falls risk, (2) Uncontrolled hypertension (SBP >180), (3) Recent surgery/trauma, (4) Poor medication adherence. Risk-benefit assessment using HAS-BLED score recommended. DOACs preferred over warfarin in most cases per 2020 ESC/AHA guidelines.",
      "agent_metadata": {
        "name": "Medical Specialist",
        "tier": 1,
        "specialties": ["cardiology", "clinical_medicine"],
        "domain": "medical"
      },
      "rag_results": [
        {
          "similarity": 0.93,
          "metadata": {
            "document_type": "clinical_guideline",
            "evidence_level": 1,
            "specialty": "cardiology"
          }
        },
        {
          "similarity": 0.90,
          "metadata": {
            "document_type": "medical_literature",
            "evidence_level": 1,
            "specialty": "clinical_medicine"
          }
        },
        {
          "similarity": 0.87,
          "metadata": {
            "document_type": "clinical_standard",
            "evidence_level": 2,
            "specialty": "cardiology"
          }
        }
      ],
      "ground_truth_confidence": 0.93,
      "ground_truth_quality": "high",
      "reasoning": "Tier 1 medical specialist with perfect specialty match, high-quality clinical guidelines, comprehensive response with absolute/relative contraindications, risk scoring (HAS-BLED), and guideline citations",
      "expected_breakdown": {
        "rag_confidence": "0.92-0.96",
        "alignment_confidence": "0.90-0.95",
        "completeness_confidence": "0.92-0.96"
      }
    },

    {
      "id": "val_006",
      "domain": "medical",
      "query": "When should anticoagulation be avoided?",
      "response": "Anticoagulation should be avoided in patients with active bleeding.",
      "agent_metadata": {
        "name": "Medical Specialist",
        "tier": 1,
        "specialties": ["general_medicine"],
        "domain": "medical"
      },
      "rag_results": [
        {
          "similarity": 0.62,
          "metadata": {
            "document_type": "general_guidance",
            "evidence_level": 4
          }
        }
      ],
      "ground_truth_confidence": 0.42,
      "ground_truth_quality": "low",
      "reasoning": "Tier 1 agent but extremely incomplete response (only mentions one contraindication), poor RAG quality, no specialty match, lacks clinical detail and guidelines",
      "expected_breakdown": {
        "rag_confidence": "0.30-0.45",
        "alignment_confidence": "0.55-0.70",
        "completeness_confidence": "0.20-0.35"
      }
    },

    {
      "id": "val_007",
      "domain": "regulatory",
      "query": "What are the Quality System Regulation (QSR) requirements for medical device manufacturers?",
      "response": "FDA QSR (21 CFR Part 820) requirements include: (1) Management Controls - quality policy, planning, review, (2) Design Controls - design planning, input, output, review, verification, validation, transfer, changes, history file (DHF), (3) Document Controls - procedures, document changes, approval, distribution, (4) Purchasing Controls - supplier evaluation, purchasing data, (5) Production and Process Controls - manufacturing procedures, environmental controls, equipment maintenance, (6) CAPA - corrective and preventive action system, (7) Records - Device Master Record (DMR), Device History Record (DHR), Quality System Record (QSR). ISO 13485 harmonization recommended for international markets.",
      "agent_metadata": {
        "name": "Regulatory Expert",
        "tier": 1,
        "specialties": ["quality_assurance", "fda_regulatory"],
        "domain": "regulatory"
      },
      "rag_results": [
        {
          "similarity": 0.95,
          "metadata": {
            "document_type": "regulatory_standard",
            "evidence_level": 1,
            "specialty": "quality_assurance"
          }
        },
        {
          "similarity": 0.92,
          "metadata": {
            "document_type": "regulatory_guidance",
            "evidence_level": 1,
            "specialty": "fda_regulatory"
          }
        },
        {
          "similarity": 0.89,
          "metadata": {
            "document_type": "iso_standard",
            "evidence_level": 1,
            "specialty": "quality_assurance"
          }
        }
      ],
      "ground_truth_confidence": 0.95,
      "ground_truth_quality": "high",
      "reasoning": "Tier 1 regulatory expert, perfect specialty match, exceptional RAG quality with regulatory standards, comprehensive response covering all major QSR subsystems with CFR citation and ISO harmonization note",
      "expected_breakdown": {
        "rag_confidence": "0.94-0.98",
        "alignment_confidence": "0.92-0.96",
        "completeness_confidence": "0.94-0.97"
      }
    },

    {
      "id": "val_008",
      "domain": "regulatory",
      "query": "What is QSR?",
      "response": "QSR is the Quality System Regulation that medical device manufacturers must follow.",
      "agent_metadata": {
        "name": "General Agent",
        "tier": 3,
        "specialties": ["general"],
        "domain": "general"
      },
      "rag_results": [
        {
          "similarity": 0.55,
          "metadata": {
            "document_type": "general_guidance",
            "evidence_level": 5
          }
        }
      ],
      "ground_truth_confidence": 0.32,
      "ground_truth_quality": "low",
      "reasoning": "Tier 3 general agent, no specialty match, very poor RAG quality, extremely superficial response with no detail on QSR components or requirements",
      "expected_breakdown": {
        "rag_confidence": "0.25-0.40",
        "alignment_confidence": "0.35-0.50",
        "completeness_confidence": "0.15-0.30"
      }
    },

    {
      "id": "val_009",
      "domain": "clinical",
      "query": "What are the statistical considerations for non-inferiority trial design in oncology?",
      "response": "Non-inferiority trials in oncology require: (1) Pre-specified non-inferiority margin (Δ) based on historical data and clinical judgment, typically preserving 50% of control treatment effect, (2) One-sided hypothesis testing (α=0.025), (3) Sample size calculation accounting for expected hazard ratio and power (typically 80-90%), (4) Intent-to-treat (ITT) analysis as primary with per-protocol (PP) as sensitivity, (5) Survival endpoints (OS, PFS) with time-to-event analysis, (6) Handling of missing data and censoring, (7) Interim analyses with alpha spending function. FDA Oncology Guidance (2019) and ICH E10 provide detailed recommendations.",
      "agent_metadata": {
        "name": "Clinical Researcher",
        "tier": 2,
        "specialties": ["biostatistics", "clinical_research", "oncology"],
        "domain": "clinical"
      },
      "rag_results": [
        {
          "similarity": 0.91,
          "metadata": {
            "document_type": "statistical_guidance",
            "evidence_level": 1,
            "specialty": "biostatistics"
          }
        },
        {
          "similarity": 0.88,
          "metadata": {
            "document_type": "clinical_guidance",
            "evidence_level": 1,
            "specialty": "oncology"
          }
        },
        {
          "similarity": 0.85,
          "metadata": {
            "document_type": "ich_guidance",
            "evidence_level": 1,
            "specialty": "clinical_research"
          }
        },
        {
          "similarity": 0.82,
          "metadata": {
            "document_type": "research_protocol",
            "evidence_level": 2,
            "specialty": "biostatistics"
          }
        }
      ],
      "ground_truth_confidence": 0.88,
      "ground_truth_quality": "high",
      "reasoning": "Tier 2 agent with excellent specialty match (biostatistics), high-quality regulatory and statistical guidance, comprehensive technical response with specific methodological details and regulatory citations. Tier 2 prevents reaching 0.90+.",
      "expected_breakdown": {
        "rag_confidence": "0.88-0.92",
        "alignment_confidence": "0.85-0.90",
        "completeness_confidence": "0.88-0.92"
      }
    },

    {
      "id": "val_010",
      "domain": "clinical",
      "query": "How do you design non-inferiority trials?",
      "response": "Non-inferiority trials compare a new treatment to an active control to show it's not worse by more than a pre-defined margin. You need to set the margin, calculate sample size, and analyze using appropriate statistics.",
      "agent_metadata": {
        "name": "Clinical Researcher",
        "tier": 2,
        "specialties": ["clinical_research"],
        "domain": "clinical"
      },
      "rag_results": [
        {
          "similarity": 0.71,
          "metadata": {
            "document_type": "general_guidance",
            "evidence_level": 3
          }
        },
        {
          "similarity": 0.68,
          "metadata": {
            "document_type": "general_guidance",
            "evidence_level": 4
          }
        }
      ],
      "ground_truth_confidence": 0.58,
      "ground_truth_quality": "medium",
      "reasoning": "Tier 2 agent, partial specialty match, medium RAG quality, response covers basic concepts but lacks technical detail (no mention of ITT/PP, alpha levels, specific margin calculation methods, or regulatory guidance)",
      "expected_breakdown": {
        "rag_confidence": "0.65-0.75",
        "alignment_confidence": "0.60-0.70",
        "completeness_confidence": "0.45-0.60"
      }
    }
  ],

  "additional_samples": [
    {
      "id": "val_011",
      "domain": "regulatory",
      "query": "What are the requirements for clinical trials under IDE regulations?",
      "ground_truth_confidence": 0.89,
      "ground_truth_quality": "high",
      "notes": "Tier 1 regulatory, high RAG quality, comprehensive IDE requirements"
    },
    {
      "id": "val_012",
      "domain": "medical",
      "query": "What are the diagnostic criteria for heart failure with preserved ejection fraction?",
      "ground_truth_confidence": 0.91,
      "ground_truth_quality": "high",
      "notes": "Tier 1 medical, specialty match cardiology, excellent clinical guidelines"
    },
    {
      "id": "val_013",
      "domain": "clinical",
      "query": "What are adaptive trial designs?",
      "ground_truth_confidence": 0.76,
      "ground_truth_quality": "medium",
      "notes": "Tier 2 clinical researcher, good RAG, adequate response but missing advanced details"
    },
    {
      "id": "val_014",
      "domain": "regulatory",
      "query": "What is MDR?",
      "ground_truth_confidence": 0.35,
      "ground_truth_quality": "low",
      "notes": "Tier 3 general, poor RAG, minimal response"
    },
    {
      "id": "val_015",
      "domain": "medical",
      "query": "What are the stages of chronic kidney disease?",
      "ground_truth_confidence": 0.87,
      "ground_truth_quality": "high",
      "notes": "Tier 1 medical nephrology specialist, high-quality clinical guidelines"
    }
  ],

  "validation_instructions": {
    "usage": "Use this dataset to validate confidence calculation accuracy",
    "acceptance_criteria": {
      "overall_accuracy": ">=85% of samples within ±0.10 of ground truth",
      "high_quality_accuracy": ">=90% of high quality samples within ±0.08",
      "low_quality_accuracy": ">=80% of low quality samples within ±0.12",
      "no_false_highs": "Zero samples with calculated >0.85 when ground truth <0.60",
      "no_false_lows": "Zero samples with calculated <0.60 when ground truth >0.85"
    },
    "test_procedure": [
      "1. Load dataset samples",
      "2. For each sample, run confidence calculation with provided inputs",
      "3. Compare calculated confidence to ground_truth_confidence",
      "4. Calculate absolute error: |calculated - ground_truth|",
      "5. Check if error within acceptable threshold (±0.10 for overall)",
      "6. Aggregate results and calculate accuracy percentage",
      "7. Identify systematic biases (over-confident or under-confident)",
      "8. Generate validation report with per-domain and per-tier analysis"
    ],
    "error_analysis": {
      "acceptable_error": "±0.10 (10 percentage points)",
      "concerning_error": ">±0.15 (requires investigation)",
      "critical_error": ">±0.25 (requires immediate fix)",
      "bias_threshold": "Mean error >±0.05 indicates systematic bias"
    }
  },

  "metadata_statistics": {
    "total_fully_labeled_samples": 10,
    "additional_samples_planned": 110,
    "distribution": {
      "by_quality": {
        "high": 5,
        "medium": 2,
        "low": 3
      },
      "by_domain": {
        "regulatory": 4,
        "clinical": 4,
        "medical": 2
      },
      "by_tier": {
        "tier_1": 6,
        "tier_2": 3,
        "tier_3": 1
      }
    },
    "confidence_ranges": {
      "0.85-0.95": 5,
      "0.65-0.84": 2,
      "0.30-0.64": 3
    }
  }
}
